Ishizaki, Tetsuo et al. published their research in Anticancer Research in 2021 |CAS: 65-71-4

The Article related to metastatic colorectal cancer trifluridine tipiracil hydrochloride bevacizumab chemotherapy, clin trial phase 2 adverse svent biweekly, biweekly, tas-102, bevacizumab, metastatic colorectal cancer, neutropenia and other aspects.Application In Synthesis of 5-Methylpyrimidine-2,4(1H,3H)-dione

On April 30, 2021, Ishizaki, Tetsuo; Mazaki, Junichi; Enomoto, Masanobu; Shigoka, Masatoshi; Kasahara, Kenta; Matsudo, Takaaki; Kawakita, Hideaki; Nagakawa, Yuichi; Katsumata, Kenji; Tsuchida, Akihiko published an article.Application In Synthesis of 5-Methylpyrimidine-2,4(1H,3H)-dione The title of the article was Prospective multicenter phase II study of biweekly TAS-102 and bevacizumab for metastatic colorectal cancer. And the article contained the following:

This study assessed the efficacy and safety of biweekly trifluridine and tipiracil hydrochloride (TAS-102) with bevacizumab combination therapy for patients with metastatic colorectal cancer (mCRC). We included 19 patients with mCRC who received TAS-102 and bevacizumab combination therapy biweekly as third-line chemotherapy. The primary endpoint was progression-free survival. Patients had a median age of 73 years and most (73.4%) were men. The median progression-free and overall survival were 5.6 and 11.5 mo, resp. Five (26.3%) patients achieved a response and the disease control rate was 12/19 (63.1%). One patient (5.2%) experienced neutropenia grade 3 or more. The median time from baseline performance status 0/1 to worsening to 2 or more was 10.3 mo. Biweekly TAS-102 plus bevacizumab facilitates tumor shrinkage by reducing the incidence of grade 3 or more neutropenia, improving survival, and maintaining performance status. This combination may represent a treatment option for patients with late-stage rnCRC receiving third- or later-line therapy. The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Application In Synthesis of 5-Methylpyrimidine-2,4(1H,3H)-dione

The Article related to metastatic colorectal cancer trifluridine tipiracil hydrochloride bevacizumab chemotherapy, clin trial phase 2 adverse svent biweekly, biweekly, tas-102, bevacizumab, metastatic colorectal cancer, neutropenia and other aspects.Application In Synthesis of 5-Methylpyrimidine-2,4(1H,3H)-dione

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia